Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 5 (2008), Issue 2 (February)

1. Percutaneous needle biopsy of lung nodules under CT fluoroscopic guidance with use of the "I-I device".
   Br J Radiol, 81(962): 107-12. [Abstract] [Full-text]
2. The tumor suppressor LKB1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity.
   Cancer Res, 68(3): 740-8. [Abstract] [Full-text]
3. Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer.
   Future Oncol, 4(1): 51-9. [Abstract] [Full-text]
4. A case-control study of the association of the polymorphisms and haplotypes of DNA ligase I with lung and upper-aerodigestive-tract cancers.
   Int J Cancer, 122(7): 1630-8. [Abstract] [Full-text]
5. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
   Int J Cancer, 122(7): 1530-8. [Abstract] [Full-text]
6. Expression of alpha CP-4 inhibits cell cycle progression and suppresses tumorigenicity of lung cancer cells.
   Int J Cancer, 122(7): 1512-20. [Abstract] [Full-text]
7. Anticancer agent CHS-828 inhibits cellular synthesis of NAD.
   Biochem Biophys Res Commun, 367(4): 799-804. [Abstract] [Full-text]
8. Minimally invasive endoscopic staging of suspected lung cancer.
   JAMA, 299(5): 540-6. [Abstract] [Full-text]
9. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming.
   Proc Natl Acad Sci U S A, 105(5): 1650-5. [Abstract] [Full-text]
10. EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy.
    Oncogene, 27(7): 957-65. [Abstract] [Full-text]
11. Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers.
    Ann Surg Oncol, 15(3): 889-99. [Abstract] [Full-text]
12. Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis.
    Cancer Invest, 26(2): 168-72. [Abstract] [Full-text]
13. Proteomic approach to biomarker discovery in cancer tissue from lung adenocarcinoma among nonsmoking Chinese women in Hong Kong.
    Cancer Invest, 26(2): 128-35. [Abstract] [Full-text]
14. Local correlation between monte-carlo dose and radiation-induced fibrosis in lung cancer patients.
    Int J Radiat Oncol Biol Phys, 70(3): 921-30. [Abstract] [Full-text]
15. Has the pattern of practice in the prescription of radiotherapy for the palliation of thoracic symptoms changed between 1999 and 2006 at the rapid response radiotherapy program?
    Int J Radiat Oncol Biol Phys, 70(3): 693-700. [Abstract] [Full-text]
16. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer.
    Int J Radiat Oncol Biol Phys, 70(3): 685-92. [Abstract] [Full-text]
17. Complications after lung radiofrequency ablation: risk factors for lung inflammation.
    Br J Radiol, 81(963): 244-9. [Abstract] [Full-text]
18. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
    J Clin Oncol, 26(6): 983-94. [Abstract] [Full-text]
19. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival.
    J Clin Oncol, 26(6): 877-83. [Abstract] [Full-text]
20. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.
    J Clin Oncol, 26(6): 870-6. [Abstract] [Full-text]
21. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
    J Clin Oncol, 26(6): 863-9. [Abstract] [Full-text]
22. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer.
    J Clin Oncol, 26(6): 856-62. [Abstract] [Full-text]
23. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
    J Clin Oncol, 26(6): 848-55. [Abstract] [Full-text]
24. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer.
    Cancer Res, 68(4): 1119-27. [Abstract] [Full-text]
25. Silencing of DUOX NADPH oxidases by promoter hypermethylation in lung cancer.
    Cancer Res, 68(4): 1037-45. [Abstract] [Full-text]
26. Growth suppression of lung cancer cells by targeting cyclic AMP response element-binding protein.
    Cancer Res, 68(4): 981-8. [Abstract] [Full-text]
27. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response.
    Cancer Res, 68(4): 965-70. [Abstract] [Full-text]
28. Leveraging primary care in the fight against lung cancer.
    J Gen Intern Med, 23(3): 344-7. [Abstract] [Full-text]
29. Rare case of hemangiopericytoma responds to sunitinib.
    Transl Res, 151(3): 129-33. [Abstract] [Full-text]
30. Failure of catalase to protect against aflatoxin B1-induced mouse lung tumorigenicity.
    Toxicol Appl Pharmacol, 227(2): 179-83. [Abstract] [Full-text]
31. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib.
    Clin Pharmacol Ther, 83(3): 477-84. [Abstract] [Full-text]
32. TAK1 is required for TGF-beta 1-mediated regulation of matrix metalloproteinase-9 and metastasis.
    Oncogene, 27(9): 1198-207. [Abstract] [Full-text]
33. Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid.
    Int J Dermatol, 47(3): 276-9. [Abstract] [Full-text]
34. Superior and basal segment lung cancers in the lower lobe have different lymph node metastatic pathways and prognosis.
    Ann Thorac Surg, 85(3): 1026-31. [Abstract] [Full-text]
35. Are surgical outcomes for lung cancer resections improved at teaching hospitals?
    Ann Thorac Surg, 85(3): 1015-24; discussion 1024-5. [Abstract] [Full-text]
36. High-dose thoracic radiation therapy at 3.0 Gy/fraction in inoperable stage I/II non-small cell lung cancer.
    Jpn J Clin Oncol, 38(2): 92-8. [Abstract] [Full-text]
37. Salvage combination chemotherapy with docetaxel, ifosfamide and cisplatin (DIP): successful treatment of a case with metastatic testicular immature teratoma.
    Jpn J Clin Oncol, 38(2): 143-5. [Abstract] [Full-text]
38. Survival after surgery in stage IA and IB non-small cell lung cancer.
    Am J Respir Crit Care Med, 177(5): 516-23. [Abstract] [Full-text]
39. Long-term use of supplemental multivitamins, vitamin C, vitamin E, and folate does not reduce the risk of lung cancer.
    Am J Respir Crit Care Med, 177(5): 524-30. [Abstract] [Full-text]
40. Endoscopic ultrasound reduces surgical mediastinal staging in lung cancer: a randomized trial.
    Am J Respir Crit Care Med, 177(5): 531-5. [Abstract] [Full-text]
41. Modulation by bexarotene of mRNA expression of genes in mouse lung tumors.
    Mol Carcinog, 47(3): 165-71. [Abstract] [Full-text]
42. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors.
    Biochem Biophys Res Commun, 368(2): 318-22. [Abstract] [Full-text]
43. Predictors of sustained smoking cessation: a prospective analysis of chronic smokers from the alpha-tocopherol Beta-carotene cancer prevention study.
    Am J Public Health, 98(3): 549-55. [Abstract] [Full-text]
44. Pediatric thyroid cancer arising after treatment for pleuropulmonary blastoma.
    Pediatr Blood Cancer, 50(4): 901-2. [Abstract] [Full-text]
45. Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing.
    Int J Cancer, 122(8): 1810-9. [Abstract] [Full-text]
46. Natural agents targeting the alpha7-nicotinic-receptor in NSCLC: a promising prospective in anti-cancer drug development.
    Int J Cancer, 122(8): 1911-5. [Abstract] [Full-text]
47. Antiangiogenic therapy in nonsmall cell lung cancer.
    Curr Opin Oncol, 20(2): 176-82. [Abstract] [Full-text]
48. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes.
    Curr Opin Oncol, 20(2): 162-75. [Abstract] [Full-text]
49. The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer.
    Curr Opin Oncol, 20(2): 155-61. [Abstract] [Full-text]
50. Neuroendocrine tumors of the lung.
    Curr Opin Oncol, 20(2): 148-54. [Abstract] [Full-text]
51. Case-control study of lung cancer risk from residential radon exposure in Worcester county, Massachusetts.
    Health Phys, 94(3): 228-41. [Abstract] [Full-text]
52. Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience.
    Ann Oncol, 19(3): 533-7. [Abstract] [Full-text]
53. Placental-site trophoblastic tumors: a case of resistant pulmonary metastasis.
    Nat Clin Pract Oncol, 5(3): 171-5. [Abstract] [Full-text]
54. Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells.
    Oncogene, 27(10): 1461-71. [Abstract] [Full-text]
55. Frequent nuclear expression of beta-catenin protein but rare beta-catenin mutation in pulmonary sclerosing haemangioma.
    J Clin Pathol, 61(3): 268-71. [Abstract] [Full-text]
56. Solitary pulmonary nodules: meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy.
    Radiology, 246(3): 772-82. [Abstract] [Full-text]
57. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure.
    Thorax, 63(3): 228-33. [Abstract] [Full-text]

© 2004-2008 Lung Cancer Research Today. All Rights Reserved.